No benefit of OSI-7904L for gastro-oesophageal cancer

摘要

The researchers took plasma samples for thymidylate synthase genotype from 37 patients, which showed no correlation between thymidylate synthase genotype, single-nucleotide polymorphisms immunohistochemistry studies, or expression in terms of time to progression or grade of toxic effects."The results of this study are disappointing. The activity of this agent is no better than might be expected from other thymidylate synthase inhibitors, such as fluorouracil", comments David Cunningham (Royal Marsden Hospital, Sutton, UK). But "the degree of disease stabilisation and duration of treatment seen might suggest that OSI-7904L could be an alternative for patients who are unable to tolerate more intensive therapy".